Search Results

You are looking at 21 - 30 of 295 items for :

Clear All
Full access

Erica L. Mayer, Nancy U. Lin and Harold J. Burstein

Yeon C Ku N . Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF) . Breast Cancer Res Treat 2004 ; 88 ( supp 1 ): S124

Full access

Kyaw Z. Thein, Somedeb Ball, Sriman Swarup, Anita Sultan, Myo H. Zaw, Lukman Tijani, Sanjay Awasthi, Fred Hardwicke and Catherine Jones

Introduction: Ribociclib, a cyclin-dependent kinase 4/6 inhibitor, has improved survival in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER 2)-negative advanced breast cancer. Despite remarkable efficacy

Full access

Ronan J. Kelly

completed enrollment but had not been presented at the time of writing, is the phase III RTOG-1010 trial ( ClinicalTrials.gov identifier: NCT01196390 ) evaluating the addition of trastuzumab to trimodality therapy in HER2-overexpressing esophageal and GEJ

Full access

Huei-Ting Tsai, Claudine Isaacs, Filipa C. Lynce, Suzanne C. O'Neill, Chunfu Liu, Marc D. Schwartz, Nandini Selvam, Yingjun Zhou and Arnold L. Potosky

Background The administration of trastuzumab, a humanized monoclonal antibody targeting HER2 on the surface of cancer cells, significantly improves survival among patients with HER2-positive breast cancer. Based on results from a joint

Full access

Ericson Stoen, Jodi Kagihara, Peter Kabos, Christine Fisher and Jennifer R. Diamond

Background: HER2-positive breast cancer historically carried a poor prognosis, though the development of HER2-targeted agents has greatly improved clinical outcomes. The APHINITY trial demonstrated a small but statistically significant improvement

Full access

Benigno Emmanuel Rodriguez Soto, Lorena López Zepeda, Alejandro Noguez Ramos, Daniela Vázquez Juarez, Daniela Shveid Gerson, Yazmin Carolina Blanco Vázquez, Samuel Rivera Rivera, Alberto Villalobos Prieto, Gabriela Olivia Regalado Porras, Ivonne Salcedo Sullk, Fernando Pérez Zincer, Christian Patricio Camacho Limas, Juan Alberto Serrano Olvera, Álvaro Aguayo González, Guillermo Manuel Olivares Beltrán and Raquel Gerson Cwilich

Background: In 2018 breast cancer was the 2nd most diagnosed malignancy worldwide and leading cause of cancer-associated death in women in Mexico. The most common subtype is hormone receptor positive/HER2 negative (HR+/HER2-). Adding a cyclin

Full access

Melinda L. Telli and Ronald M. Witteles

T rastuzumab, a humanized monoclonal antibody against the extracellular domain of the human epidermal growth factor receptor 2 (HER2), has dramatically impacted the natural history of HER2-positive breast cancer in both the metastatic and early

Full access

Ju Wang, Ye Zhang, Long Yuan, Lin Ren, Yi Zhang and Xiaowei Qi

Background: Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide in women. Both Talazoparib and Olaparib are approved by FDA for BRCA mutated HER2-negative metastatic or advanced breast cancer patients

Full access

Aki Morikawa and Andrew D. Seidman

Contemporary systemic therapy is commonly informed by the classification of breast cancer based solely on hormonal receptor and HER2 status. Triple-negative is a category of exclusion defined by immunohistochemical and/or fluorescence in situ

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy and Cynthia X. Ma

–positive (HR+) and HER2-negative (HER2–) breast cancer. Since the initial FDA approval in February 2015 of palbociclib in combination with letrozole in the first-line setting based on data from the PALOMA-1 trial, 6 , 7 several phase III randomized trials have